MX2015008138A - Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis. - Google Patents
Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis.Info
- Publication number
- MX2015008138A MX2015008138A MX2015008138A MX2015008138A MX2015008138A MX 2015008138 A MX2015008138 A MX 2015008138A MX 2015008138 A MX2015008138 A MX 2015008138A MX 2015008138 A MX2015008138 A MX 2015008138A MX 2015008138 A MX2015008138 A MX 2015008138A
- Authority
- MX
- Mexico
- Prior art keywords
- dimethylpropan
- carboxy
- ethyl
- aminium
- pharmaceutically acceptable
- Prior art date
Links
- ISMYCKWHOZKHNJ-UHFFFAOYSA-O 3-carboxypropyl-ethyl-dimethylazanium Chemical compound CC[N+](C)(C)CCCC(O)=O ISMYCKWHOZKHNJ-UHFFFAOYSA-O 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- PPDPFXLNXLDRNM-WLHGVMLRSA-N (e)-but-2-enedioate;3-carboxypropyl-ethyl-dimethylazanium;hydron Chemical compound OC(=O)\C=C\C([O-])=O.CC[N+](C)(C)CCCC(O)=O PPDPFXLNXLDRNM-WLHGVMLRSA-N 0.000 abstract 1
- DQSCWIHGBKJVRY-UHFFFAOYSA-N 3-carboxypropyl-ethyl-dimethylazanium;dihydrogen phosphate Chemical compound OP(O)([O-])=O.CC[N+](C)(C)CCCC(O)=O DQSCWIHGBKJVRY-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium and its pharmaceutically acceptable salts: 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium hydrogen fumarate and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate, in the prevention and treatment atherosclerosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198627 | 2012-12-20 | ||
| PCT/EP2013/077291 WO2014096133A1 (en) | 2012-12-20 | 2013-12-19 | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008138A true MX2015008138A (en) | 2016-04-25 |
| MX362762B MX362762B (en) | 2019-02-06 |
Family
ID=47458734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008138A MX362762B (en) | 2012-12-20 | 2013-12-19 | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis. |
Country Status (11)
| Country | Link |
|---|---|
| CN (1) | CN104869988B (en) |
| AR (1) | AR094084A1 (en) |
| BR (1) | BR112015014161B1 (en) |
| CA (1) | CA2895574C (en) |
| CU (1) | CU20150067A7 (en) |
| JO (1) | JO3117B1 (en) |
| MX (1) | MX362762B (en) |
| PE (1) | PE20151587A1 (en) |
| TN (1) | TN2015000236A1 (en) |
| WO (1) | WO2014096133A1 (en) |
| ZA (1) | ZA201505093B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010149654A1 (en) * | 2009-06-25 | 2010-12-29 | Grindeks, A Joint Stock Company | Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt |
| WO2010151095A1 (en) * | 2009-06-25 | 2010-12-29 | Tetra, Sia | Novel acetylsalicylic acid salts |
| LV14345B (en) * | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4-[ethyl(dimethyl)ammonio]butanoate and their use in the treatment of cardiovascular diseases |
| RS55092B1 (en) * | 2011-04-27 | 2016-12-30 | Grindeks Jsc | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
-
2013
- 2013-12-11 JO JOP/2013/0362A patent/JO3117B1/en active
- 2013-12-18 AR ARP130104820A patent/AR094084A1/en unknown
- 2013-12-19 MX MX2015008138A patent/MX362762B/en active IP Right Grant
- 2013-12-19 WO PCT/EP2013/077291 patent/WO2014096133A1/en active Application Filing
- 2013-12-19 BR BR112015014161-7A patent/BR112015014161B1/en active IP Right Grant
- 2013-12-19 CA CA2895574A patent/CA2895574C/en active Active
- 2013-12-19 PE PE2015000876A patent/PE20151587A1/en not_active Application Discontinuation
- 2013-12-19 CN CN201380066810.0A patent/CN104869988B/en active Active
-
2015
- 2015-06-01 TN TNP2015000236A patent/TN2015000236A1/en unknown
- 2015-06-19 CU CUP2015000067A patent/CU20150067A7/en unknown
- 2015-07-15 ZA ZA2015/05093A patent/ZA201505093B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2895574C (en) | 2019-11-26 |
| CN104869988A (en) | 2015-08-26 |
| BR112015014161B1 (en) | 2021-02-17 |
| MX362762B (en) | 2019-02-06 |
| AR094084A1 (en) | 2015-07-08 |
| CA2895574A1 (en) | 2014-06-26 |
| BR112015014161A2 (en) | 2017-07-11 |
| WO2014096133A1 (en) | 2014-06-26 |
| TN2015000236A1 (en) | 2016-10-03 |
| JO3117B1 (en) | 2017-09-20 |
| CN104869988B (en) | 2017-07-28 |
| ZA201505093B (en) | 2016-04-28 |
| CU20150067A7 (en) | 2016-01-29 |
| PE20151587A1 (en) | 2015-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3343B1 (en) | Novel5-aminotetrahydroquinoline-2-carboxylic acids and their use | |
| SG195110A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| SG10201901010PA (en) | Combination therapy for treating a paramyxovirus | |
| SA515360469B1 (en) | Heterocyclic compounds for inhibiting glutaminase and their methods of use | |
| IN2015DN00895A (en) | ||
| IN2015DN01156A (en) | ||
| PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| PH12015502042B1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| MX356525B (en) | Aav -vectors for use in gene therapy of choroideremia. | |
| TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| MX2013008737A (en) | Oral dosage forms for modified release comprising tasocitinib. | |
| MY166936A (en) | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder | |
| MX351464B (en) | Methods for the treatment of allergic diseases. | |
| PT2848097T (en) | Device for the plasma treatment of human, animal or plant surfaces, in particular of skin or mucous membrane areas | |
| TW201144301A (en) | Processes for preparing linezolid | |
| IN2014DN10670A (en) | ||
| WO2013098416A3 (en) | Pain relief compounds | |
| TN2012000610A1 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
| MX364220B (en) | Methods of treating fibrosis. | |
| GEP20196984B (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| MX359181B (en) | Collagen hydrolysate and use thereof. | |
| MX2015013755A (en) | Pharmaceutical formulation for use in the treatment and/or prevention of restenosis. | |
| MX2015007945A (en) | Uses and methods for the treatment of liver diseases or conditions. | |
| AU2012307449A8 (en) | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | |
| MX362111B (en) | A method of improving liver function. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |